Results 141 to 150 of about 224,203 (310)
Advanced Intelligent Systems, Volume 7, Issue 3, March 2025.Magnetic soft robots offer promise in biomedicine due to their wireless actuation and rapid response, but current fabrication methods are complex and have limited cellular compatibility. A new, contactless bioassembly strategy using hydrodynamic instabilities is introduced, enabling customizable, centimeter‐scale robots.
Wei Gao +5 more
wiley +1 more source
Gene therapy: efficient targeting of hematopoietic stem cells
, 2005 Lentiviral vectors containing recombinant envelope proteins that target hematopoietic stem cells have now been engineered to increase the efficiency of gene ...
Karlsson, Stefan
core
, 2015 In the adult, the source of functionally diverse, mature blood cells are hematopoietic stem cells, a rare population of quiescent cells that reside in the bone marrow niche.
Cary Weiss, Keisuke Ito
core +1 more source
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
American Journal of Hematology, EarlyView.ABSTRACT Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited.
Shahla Vilcassim +13 more
wiley +1 more source
Prion Protein is Expressed on Long-term Repopulating Hematopoietic Stem Cells and is Necessary for their Self-renewal [PDF]
, 2005 We show that the prion protein (PrP) is expressed on the surface of bone marrow cell populations enriched in long-term repopulating hematopoietic stem cells.
Steele, Andrew D. +3 more
core
American Journal of Hematology, EarlyView.Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig +25 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima +48 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management
American Journal of Hematology, EarlyView.ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source